Marcia Belvin - 22 Mar 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Issuer symbol
CTMX
Transactions as of
22 Mar 2023
Net transactions value
$0
Form type
4
Filing time
29 Mar 2023, 19:54:34 UTC
Next filing
22 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +60,000 +74% $0.000000 140,820 22 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2024, subject to the Reporting Person continuing as a service provider through each such date.
F2 Includes 116,875 RSUs.